Related Experiment Videos
The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications
Abstract:
Data are presented showing that human prostatic adenocarcinoma depends on dihydrotestosterone (DHT) and not testosterone (T) for growth. It follows that androgen ablative therapy should be directed toward elimination of DHT with retention of circulating T. This can be achieved by using a 5 alpha-reductase inhibitor such as 6-methyleneprogesterone (6-MP) (VII). Arguments are presented showing that 6-MP (VII) is expected 1) to function as a prophylactic agent against prostate cancer, 2) to represent an attractive therapeutic modality for palliative treatment of the hormone-responsive disease, and 3) to be compatible with other therapeutic modalities when very low prostatic levels of DHT should be within reach.
Insights
Human prostate cancer growth relies on dihydrotestosterone (DHT), not testosterone (T). Androgen ablative therapy should target DHT elimination using 5 alpha-reductase inhibitors like 6-methyleneprogesterone (6-MP) for effective treatment and prevention.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Human prostatic adenocarcinoma growth is androgen-dependent.
- Testosterone (T) is converted to dihydrotestosterone (DHT), the primary androgen driving prostate cancer growth.
Purpose of the Study:
- To investigate the role of DHT versus T in prostate cancer growth.
- To propose a therapeutic strategy targeting DHT elimination.
Main Methods:
- The study presents data on the dependence of prostatic adenocarcinoma on DHT.
- It discusses the mechanism of action for 5 alpha-reductase inhibitors.
Main Results:
- Human prostatic adenocarcinoma growth is dependent on DHT, not T.
- 6-methyleneprogesterone (6-MP) is identified as a 5 alpha-reductase inhibitor capable of eliminating DHT.
Conclusions:
- Androgen ablative therapy should focus on DHT elimination while preserving T levels.
- 6-MP shows potential as a prophylactic agent, a palliative treatment for hormone-responsive prostate cancer, and is compatible with other therapies.